Anbio Biotechnology

About Anbio Biotechnology

Anbio Biotechnology, founded in 2021, is dedicated to advancing medical technology through innovative in vitro diagnostics (IVD) products. Their mission is to transform the global diagnostics landscape by promoting personalized and decentralized diagnostic solutions, ultimately enhancing patient outcomes and improving healthcare worldwide.

Products & Services

In Vitro Diagnostics (IVD) Products:A diverse range of diagnostic tools for over-the-counter (OTC), point-of-care (POCT), and laboratory use, detecting biomarkers for conditions such as infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Compatible with multiple sample types including serum, plasma, whole blood, feces, urine, and saliva.

IVD Platforms:Includes five platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR), and Loop-mediated Isothermal Amplification (LAMP), enabling advanced diagnostic capabilities for healthcare professionals.

Specialties

In Vitro Diagnostics (IVD) Personalized Diagnostics Decentralized Diagnostic Solutions Chemiluminescence Immunoassay (ChLIA) Lateral Flow Immunoassay (LFIA) Fluorescent Immunoassay (FIA) Polymerase Chain Reaction (PCR) Loop-mediated Isothermal Amplification (LAMP)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: IPO T: - FT: IPO	A: 8000000 MR: - FA: US$8 million FAN: 8000000	D: 2025-02-20 FD: 2025-02-20	1 investors

IPO Latest

2025-02-20

$8.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News